A First-in-human Study of YN001 in Healthy Volunteers

Phase 1 Completed 64 enrolled Beijing Inno Medicine Co., Ltd.

RandomizedParallel-groupTriple-blindTreatment

Summary

This will be a single center, randomized, double-blind, placebo-controlled, single ascending dose and multiple ascending dose study in healthy adult subjects.

Timeline

Start: 2022-12-16
Primary completion: 2024-08-09
Completion: 2024-08-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	YN001	Unknown	—	Intravenous

A First-in-human Study of YN001 in Healthy Volunteers

Summary

Timeline

Drugs

Indications